Dear Ms. Low:

Please refer to your supplemental new drug application (sNDA) dated and received September 29, 2021 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Veklury (remdesivir) injection, 5 mg/ml, Veklury (remdesivir) for injection, 100 mg/vial.

This Prior Approval sNDA provides for the following:

- Update on the CLINICAL PHARMACOLOGY, 12.4 Microbiology subsection of the Prescribing Information with information regarding cell culture susceptibility assessments of remdesivir against several SARS-CoV-2 Variants of Concern or Interest (Alpha, B.1.1.7; Beta, B.1.351; Delta, B.1.617.2; Gamma, P.1; and Epsilon, B.1.429), SARS-CoV-2 RNA shedding (oropharyngeal or nasopharyngeal swabs) and viral load (plasma) from clinical trials, cell culture selection studies identifying potential remdesivir resistance-associated substitutions in the RNA-dependent RNA polymerase (nsp12), and identification of a treatment-emergent nsp12 substitution (E802D) that confers reduced susceptibility (2.5-fold reduction) to remdesivir.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submission dated September 29, 2021, containing the final reports for the following postmarketing requirements listed in the October 22, 2020 approval letter.

3919-2 Conduct a study to select for remdesivir resistant SARS-CoV-2 variants in cell culture and characterize several independent isolates phenotypically and genotypically.

3919-3 Submit all SARS-CoV-2 viral shedding and viral load data from ACTT-1, GS-540-5773, and GS-US-540-5774 assessing remdesivir including quantitation of viral shedding and viral load for any subject samples that have not been completed to date.

We have reviewed your submission and conclude that the above requirements were fulfilled.

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
We remind you that there are postmarketing requirements and postmarketing commitments listed in the October 22, 2020 approval letter and May 26, 2021 postapproval postmarketing requirement letter that are still open.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Saebyeol Jang, PhD, RAC, Regulatory Project Manager, at (240) 402-9953 or (301) 796-1500.

Sincerely,

[See appended electronic signature page]

Debra Birnkrant, MD
Director
Division of Antivirals
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURES:
- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

POONAM MISHRA
01/19/2022 10:03:52 AM
On behalf of Division Director